PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
10629868-5	1999	Propranolol and bopindolol have high affinity to beta 1 and beta 2 subtypes, but low affinity to beta 3 subtype.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	49-66	
9846642-14	1998	Treatment of hamsters with propranolol resulted in increased density of beta1-adrenoceptors in both strains, but had no effect on their functional efficacy.	Propranolol	27-38	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	72-77	
1541316-3	1992	Equivalent doses of the pure antagonists atenolol (beta 1) and propranolol (beta 1, beta 2) produced similar reductions in heart rate, systolic blood pressure, and cardiac index, and increases in stroke volume and total peripheral resistance, particularly during exercise.	Propranolol	63-74	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	76-90	
7701450-8	1995	Whilst propranolol blunted exercise heart rate in keeping with beta 1 blockade, salbutamol had no effect.	Propranolol	7-18	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	63-69	
8658370-7	1996	Propranolol blunted the heart rate delta response to exercise, consistent with beta 1 blockade, whilst salmeterol and formoterol had no effect.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	79-85	
7567595-9	1995	After administration of beta 1-, beta 2-blocker, propranolol (30 mg/day), cAMP at 3 minutes of tilt decreased significantly compared to the baseline tilt (16.9 +/- 1.4 pmol/mL vs 25.3 +/- 2.0 pmol/mL; P < 0.05) and propranolol prevented the syncope in all six patients.	Propranolol	218-229	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	24-31	
7912102-0	1993	Extent of beta 1- and beta 2-receptor occupancy in plasma assesses the antagonist activity of metoprolol, pindolol, and propranolol in the elderly.	Propranolol	120-131	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	10-16	
7912102-1	1993	We estimated antagonist activity of metoprolol, pindolol, and propranolol in elderly cardiovascular patients by determining the extent to which the drugs occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples during drug treatment.	Propranolol	62-73	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	175-181	
7912102-5	1993	The results and conclusions were the following: (a) The extent to which metoprolol, pindolol, and propranolol occupied rabbit lung beta 1- and rat reticulocyte beta 2-adrenoceptors in plasma samples estimated accurately the intensity of beta-receptor antagonism in the patients who did not tolerate physiological and pharmacological tests measuring the degree of beta 1- and beta 2-adrenoceptor blockade.	Propranolol	98-109	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	131-137	
7912102-6	1993	(b) The mean beta 1- and beta 2-receptor occupancy of pindolol and propranolol varied between 76% and 99% during the treatments.	Propranolol	67-78	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	13-19	
8104518-2	1993	beta 1-Adrenolytic (atria) structure-activity correlations indicated that replacement of the 1-naphthyl moiety of propranolol by a 4-quinolyl- (10), 2-quinolyl- (24), or 2-pyrimidyl- (26) heterocyclic moiety resulted in a 10-16 fold reduction in activity.	Propranolol	114-125	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	0-6	
1717272-2	1991	This effect is stereoselectively inhibited by (-)-propranolol and is inhibited also by the beta 1-selective adrenergic antagonists, bisoprolol and metoprolol.	Propranolol	46-61	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	91-97	
1659260-3	1991	Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission.	Propranolol	48-59	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	61-78	
1659260-3	1991	Aerosol administration of the beta antagonists, propranolol (beta 1 and beta 2), atenolol (beta 1), and butoxamine (beta 2) decreased dynamic compliance (Cdyn) and increased pulmonary resistance (RL) in the principal ponies during airway obstruction, but were without effect when the ponies were in clinical remission.	Propranolol	48-59	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	61-67	
1671724-3	1991	For example, propranolol is a nonselective beta-blocker with antagonist effects on both beta 1 and beta 2 receptors, atenolol is a selective beta 1-antagonist, and celiprolol is a selective beta 1-antagonist, partial beta 2-agonist.	Propranolol	13-24	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	88-94	
1845926-6	1991	Preinduction K+ changes were determined in patients given a single preoperative dose of propranolol (beta 1/beta 2-antagonist), atenolol (beta 1-antagonist), or no beta-blocker (control).	Propranolol	88-99	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	101-107	
2901818-7	1988	INTERVENTION: The beta-1-nonselective blocker was propranolol, 80 mg twice daily.	Propranolol	50-61	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	18-24	
2866062-3	1985	In a cross-over trial of placebo, atenolol (beta 1-blocker), propranolol (beta 1- and beta 2-blocker) and pindolol (beta 1- and beta 2-blocker with intrinsic sympathomimetic activity) in 11 normal men t1/2 was 11.8 +/- 0.9, 12.6 +/- 1.1, 14.3 +/- 1.7 and 12.4 +/- 1.1 min respectively.	Propranolol	61-72	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	74-80	
3520212-1	1986	We have previously shown that the increase in energy expenditure following glucose/insulin infusion is, in large part, mediated by the sympathetic nervous system and that this sympathetic component can be blocked by the nonselective beta-1, beta-2 antagonist propranolol.	Propranolol	259-270	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	233-239	
2839668-5	1988	After propranolol administration, in vitro beta-1 and beta-2 adrenoceptor occupancy declined from initially 97% to less than 10% within 48 hr.	Propranolol	6-17	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-49	
3017797-3	1986	The adrenergic receptor mediating the adrenaline effect was characterized by concomitant infusion of propranolol (beta 1 + beta 2-antagonist) or metoprolol (beta 1-antagonist).	Propranolol	101-112	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	114-120	
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Propranolol	58-69	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	25-31	
2439798-9	1986	Assessing the data for a beta 1/beta 2-splitting as 1 for propranolol, the relative beta 1-selectivity (mean +/- SEM) was 12.2 +/- 1.1 for bisoprolol, 9.0 +/- 0.9 for metoprolol, 6.2 +/- 0.6 for acebutolol, and 0.6 +/- 0.06 for penbutolol.	Propranolol	58-69	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	84-90	
6281414-9	1982	Increases in the densities of beta-1 and/or beta-2 adrenergic receptors in solid tissues may be related to some of the untoward effects observed in humans after abrupt discontinuation of propranolol administration.	Propranolol	187-198	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	30-41	
6199591-8	1984	beta-Blockade with propranolol (nonselective), 80 mg four times a day, or atenolol (beta 1-selective), 100 mg once a day, antagonized the hypokalemic effect of isoproterenol as well as the rise in norepinephrine, but when isoproterenol was infused in doses high enough to overcome the blockade of the heart rate response, the effects on norepinephrine and potassium were abolished by propranolol and not by atenolol.	Propranolol	384-395	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	84-90	
6130932-1	1983	The influence of acute beta 1-receptor blockade using 50 mg metoprolol or beta 1/beta 2-blockade using 40 mg propranolol resulted in an equipotent reduction of cardiac frequency and systolic blood pressure without influencing diastolic pressure in ten healthy probands.	Propranolol	109-120	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	23-29	
6130932-1	1983	The influence of acute beta 1-receptor blockade using 50 mg metoprolol or beta 1/beta 2-blockade using 40 mg propranolol resulted in an equipotent reduction of cardiac frequency and systolic blood pressure without influencing diastolic pressure in ten healthy probands.	Propranolol	109-120	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	74-87	
6138298-5	1983	SCC was not influenced by the beta 1-antagonist atenolol but was modified, although differently in rabbit and man, by the beta 1- and beta 2-antagonist propranolol.	Propranolol	152-163	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	122-140	
6188919-6	1983	It has been demonstrated that beta-blockers with intrinsic sympathomimetic activity (ISA), such as pindolol, and beta 1-selective blockers have a less marked effect on pulmonary function than nonselective beta-blockers without ISA, such as propranolol.	Propranolol	240-251	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	113-119	
7259364-7	1981	Under the experimental conditions of this trial, propranolol inhibited beta 1 and beta 2 receptors at the same time, whereas acebutolol inhibited only beta 1 receptors.	Propranolol	49-60	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	71-77	
6113715-2	1981	In contrast to Talinolol under the treatment ith the unspecific beta-blocker Propranolol a clear blocking of the beta 2-mediated glycogenolysis which can be evoked with the help of Orciprenalin and of the lipolysis evocable via beta 1-receptors was observed.	Propranolol	77-88	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	228-234	
190674-2	1977	In this study it was shown that tremor caused by terbutaline could be blocked by propranolol, a drug with both beta1- and beta2-blocking properties, but not by metoprolol, a beta1-selective antagonist.	Propranolol	81-92	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	111-127	
13495-2	1977	When given in equipotent beta1 blocking doses, the nonselective blocker propranolol and the beta1 selective blocker metoprolol differ markedly as regards inhibition of adrenaline induced beta2 mediated vasodilatation.	Propranolol	72-83	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	25-30	
28240622-2	2017	Propranolol, a nonselective beta1, beta2-adrenergic receptor antagonist, reduces resting heart rate and cardiac work caused by elevated circulating catecholamines.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	28-33	
31296894-4	2019	Propranolol, a non-specific beta1-and beta2-adrenergic receptor antagonist, was recently designated as the first therapeutic (orphan) drug for VHL disease.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	28-33	
29210030-6	2018	Propranolol and nadolol block the beta-1 in the heart and the peripheral beta-2 adrenergic receptors.	Propranolol	0-11	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-40	
11306460-4	2001	The beta1/2-blocker propranolol but not the beta1-blocker atenolol inhibited this increase.	Propranolol	20-31	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	4-11	
18403423-5	2008	Administration of a non-selective beta-adrenergic (beta(1) + beta(2)) receptor antagonist (propranolol) reduced heart rate (69 +/- 8 to 58 +/- 6 beats min(-1)) and exercise capacity (239 +/- 42 to 209 +/- 31 W; P < 0.05) with arterial lactate reaching 9.4 +/- 3.6 mm.	Propranolol	91-102	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	34-58	
28556385-1	2017	BACKGROUND/OBJECTIVES: The nonselective beta-blocker propranolol is the current criterion standard for treatment of infantile hemangiomas (IHs) and the first therapy that the U.S. Food and Drug Administration has approved for the condition, but concern about adverse effects, such as bronchospasm, hypoglycemia, and sleep disturbances, has sparked interest in the use of alternative agents such as the selective beta1 antagonist atenolol.	Propranolol	53-64	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	412-417	
20424515-6	2010	beta2-adrenergic antagonist ICI118,551 and beta1/2-adrenergic antagonist propranolol significantly suppressed cell invasion and proliferation in comparison to beta1-adrenergic antagonist metoprolol and control in a Matrigel invasion assay and subrenal capsular assay.	Propranolol	73-84	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-50	
20424515-6	2010	beta2-adrenergic antagonist ICI118,551 and beta1/2-adrenergic antagonist propranolol significantly suppressed cell invasion and proliferation in comparison to beta1-adrenergic antagonist metoprolol and control in a Matrigel invasion assay and subrenal capsular assay.	Propranolol	73-84	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	43-48	
17414346-1	2007	BACKGROUND: Propranolol, a nonselective beta1-2 antagonist, attenuates hypermetabolism and catabolism in severely burned patients.	Propranolol	12-23	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	40-47	
15710352-4	2005	The involvement of beta-adrenergic receptors was confirmed using the general beta(1)/beta(2) receptor antagonist propranolol, which was able to abrogate the protection conferred by isoproterenol and clenbuterol in astrocytes treated with LPS.	Propranolol	113-124	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	77-84	
11141226-13	2001	Whenever beta-blockers are chosen for treatment of hyperthyroidism, propranolol (beta 1 + beta 2) has an advantage because it reduces the metabolic rate, whereas selective beta 1-blockade seemed to provide only symptomatic relief, related to the normalization of heart rate.	Propranolol	68-79	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	81-96	
11141226-13	2001	Whenever beta-blockers are chosen for treatment of hyperthyroidism, propranolol (beta 1 + beta 2) has an advantage because it reduces the metabolic rate, whereas selective beta 1-blockade seemed to provide only symptomatic relief, related to the normalization of heart rate.	Propranolol	68-79	potassium calcium-activated channel subfamily M regulatory beta subunit 1	Homo sapiens	81-87